

Rebecca C Coll

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5917460/publications.pdf>

Version: 2024-02-01

32
papers

6,278
citations

331670

21
h-index

477307

29
g-index

38
all docs

38
docs citations

38
times ranked

10048
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Activation of the Non-canonical Inflammasome in Mouse and Human Cells. <i>Methods in Molecular Biology</i> , 2022, 2459, 51-63. | 0.9 | 3 |
| 2 | NLRP3 and pyroptosis blockers for treating inflammatory diseases. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 653-668. | 8.7 | 193 |
| 3 | PHOrming the inflammasome: phosphorylation is a critical switch in inflammasome signalling. <i>Biochemical Society Transactions</i> , 2021, 49, 2495-2507. | 3.4 | 8 |
| 4 | Caging NLRP3 tames inflammasome activity. <i>Cell</i> , 2021, 184, 6224-6226. | 28.9 | 5 |
| 5 | NLRP3 inflammasome priming: A riddle wrapped in a mystery inside an enigma. <i>Journal of Leukocyte Biology</i> , 2020, 108, 937-952. | 3.3 | 118 |
| 6 | Design, synthesis and evaluation of an NLRP3 inhibitor diazirine photoaffinity probe. <i>Tetrahedron Letters</i> , 2020, 61, 151849. | 1.4 | 7 |
| 7 | Role reversal: adaptive immunity instructs inflammasome activation for anti-viral defence. <i>EMBO Journal</i> , 2019, 38, e103533. | 7.8 | 5 |
| 8 | 1020 - NEW INSIGHTS INTO INFLAMMASOME SIGNALLING AND FUNCTION DURING INFLAMMATION. <i>Experimental Hematology</i> , 2019, 76, S32. | 0.4 | 0 |
| 9 | MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. <i>Nature Chemical Biology</i> , 2019, 15, 556-559. | 8.0 | 561 |
| 10 | Evidence against a role for NLRP3-driven islet inflammation in db/db mice. <i>Molecular Metabolism</i> , 2018, 10, 66-73. | 6.5 | 32 |
| 11 | Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity. <i>Journal of Experimental Medicine</i> , 2018, 215, 827-840. | 8.5 | 396 |
| 12 | NLR3 Restrains Responses to a T. Immunity, 2018, 49, 989-991. | 14.3 | 1 |
| 13 | Mitochondrial DNA synthesis fuels NLRP3 inflammasome. <i>Cell Research</i> , 2018, 28, 1046-1047. | 12.0 | 20 |
| 14 | Sterile signals generate weaker and delayed macrophage NLRP3 inflammasome responses relative to microbial signals. <i>Cellular and Molecular Immunology</i> , 2017, 14, 118-126. | 10.5 | 42 |
| 15 | The intracellular chloride channel proteins CLIC1 and CLIC4 induce IL-1 β transcription and activate the NLRP3 inflammasome. <i>Journal of Biological Chemistry</i> , 2017, 292, 12077-12087. | 3.4 | 122 |
| 16 | Solution structure of the TLR adaptor MAL/TIRAP reveals an intact BB loop and supports MAL Cys91 glutathionylation for signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E6480-E6489. | 7.1 | 33 |
| 17 | Sulfonylureas as Concomitant Insulin Secretagogues and NLRP3 Inflammasome Inhibitors. <i>ChemMedChem</i> , 2017, 12, 1449-1457. | 3.2 | 42 |
| 18 | The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. <i>Blood</i> , 2016, 128, 2960-2975. | 1.4 | 271 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Questions and controversies in innate immune research: what is the physiological role of NLRP3?. Cell Death Discovery, 2016, 2, 16019. | 4.7 | 48 |
| 20 | T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4 ⁺ T cells. Science, 2016, 352, aad1210. | 12.6 | 395 |
| 21 | A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature Medicine, 2015, 21, 248-255. | 30.7 | 1,967 |
| 22 | Monounsaturated Fatty Acid-Enriched High-Fat Diets Impede Adipose NLRP3 Inflammasome-Mediated IL-1 β Secretion and Insulin Resistance Despite Obesity. Diabetes, 2015, 64, 2116-2128. | 0.6 | 229 |
| 23 | A6.18...Novel compound cytokine release inhibitory drug 3 (CRID3) inhibits the NLRP3 inflammasome in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, A62.2-A63. | 0.9 | 0 |
| 24 | GSTO1-1 modulates metabolism in macrophages activated through the LPS and TLR4 pathway. Journal of Cell Science, 2015, 128, 1982-1990. | 2.0 | 55 |
| 25 | Cytokine release inhibitor drug, CRID3, inhibits the NLRP3 inflammasome in glia. Journal of Neuroimmunology, 2014, 275, 147. | 2.3 | 0 |
| 26 | Glutathione transferase Omega 1 is required for the lipopolysaccharide-stimulated induction of NADPH oxidase 1 and the production of reactive oxygen species in macrophages. Free Radical Biology and Medicine, 2014, 73, 318-327. | 2.9 | 62 |
| 27 | Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destruction. Arthritis Research and Therapy, 2014, 16, 419. | 3.5 | 86 |
| 28 | 102. Cytokine, 2013, 63, 267. | 3.2 | 0 |
| 29 | Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments. Current Opinion in Immunology, 2013, 25, 40-45. | 5.5 | 187 |
| 30 | The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 Inflammasomes. PLoS ONE, 2011, 6, e29539. | 2.5 | 117 |
| 31 | Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1 β in type 2 diabetes. Nature Immunology, 2010, 11, 897-904. | 14.5 | 1,149 |
| 32 | New Insights into the Regulation of Signalling by Toll-Like Receptors and Nod-Like Receptors. Journal of Innate Immunity, 2010, 2, 406-421. | 3.8 | 121 |